IRME · As filed with the SEC
IR-Med cash flow statement, by fiscal year
The statement as IR-Med presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 |
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net Income | (1,899) | (4,909) | (4,734) | (3,716) | (752) |
| Adjustments to reconcile loss for the year to net cash used in operating activities: | |||||
| Non-cash expense | 485 | 1,682 | 1,330 | 1,339 | — |
| Depreciation Expense | 21 | 17 | 10 | 5 | 1 |
| Net Cash from Operating Activities | — | — | — | — | 25 |
| Financial expenses | — | — | — | 11 | 20 |
| Financial expenses (income), net | 2 | (3) | (28) | — | — |
| Decrease (increase) in accounts receivable | 6 | 6 | 12 | (38) | (16) |
| Change in Accounts Payable | (1) | (25) | 35 | (83) | 320 |
| Net cash used in operating activities | (1,386) | (3,232) | (3,375) | (2,482) | (402) |
| Cash flows from investing activities | |||||
| Purchase of property and equipment | — | (2) | (50) | (31) | — |
| Increase in long term deposit | — | — | (9) | (30) | — |
| Net cash used in investing activities | — | (2) | (59) | (61) | — |
| Cash flows from financing activities | |||||
| Stock Repurchases (Issuances) | — | — | — | — | 81 |
| Repayment of shareholder loan | (5) | — | — | — | — |
| Net Cash from Financing Activities | 755 | 1,000 | 3,625 | 3,491 | 1,955 |
| Net cash provided by financing activities | 750 | 1,000 | 3,625 | 3,491 | 2,036 |
| Effect of Exchange Rate on Cash | (2) | (1) | (4) | 1 | (3) |
| Net decrease in cash and cash equivalents | (638) | (2,235) | 187 | 949 | 1,631 |
| Cash and cash equivalents as at the beginning of the year | 767 | 3,002 | 2,815 | 1,866 | 235 |
| Cash and cash equivalents as at the end of the year | 129 | 767 | 3,002 | 2,815 | 1,866 |
| Increase in other receivable from shares issuance | — | — | — | — | 189 |
| Increase in right of use assets against lease liability | — | — | 155 | — | — |
| Increase in right of use assets against long term restricted deposits | — | — | 19 | — | — |
| Decrease in trade and other payables from grant of options | — | — | — | 45 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.